IDEAYA BiosciencesIDYA +4.10%55 Current Ratio is 10.74 as of Mar. 2026, which is 13% below its 10-year median of 12.39. GuruFocus rates IDYA with a GF Score™ of 55/100 and a GF Value™ of $214.33 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,417 Biotechnology companies, IDEAYA Biosciences ranks better than 79.96% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. IDEAYA Biosciences's current ratio for the quarter that ended in Mar. 2026 was 10.74.
IDEAYA Biosciences has a current ratio of 10.74. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for IDEAYA Biosciences's Current Ratio or its related term are showing as below:
IDYA'
s Current Ratio Range Over the Past 10 Years
Min: 4.5 Med: 12.39 Max: 28.42
Current: 10.74
During the past 9 years, IDEAYA Biosciences's highest Current Ratio was 28.42. The lowest was 4.50. And the median was 12.39.
IDYA's Current Ratio is ranked better than 79.96% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs IDYA: 10.74
IDEAYA Biosciences (NAS:IDYA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
IDEAYA Biosciences Current Ratio Related Terms
IDEAYA Biosciences Current Ratio Historical Data
* Premium members only.
The historical data trend for IDEAYA Biosciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDYA vs MLYS, TARS, DFTX: Current Ratio Comparison
For the Biotechnology subindustry, IDEAYA Biosciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEAYA Biosciences Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where IDEAYA Biosciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEAYA Biosciences (IDYA) has a Current Ratio of 10.74 as of Mar. 2026. This is 13% below median its historical median of 12.39. Over the past decade, IDEAYA Biosciences' Current Ratio has ranged from 4.50 to 28.42. According to the industry distribution chart, IDEAYA Biosciences ranks #284 out of 1417 companies in the Biotechnology industry, placing it in the top 20%.
Is IDEAYA Biosciences' Current Ratio too high?
IDEAYA Biosciences' current Current Ratio of 10.74 is 13% below median its 10-year median of 12.39. Over the past 10 years, this metric has ranged from a low of 4.50 to a high of 28.42. The Biotechnology industry median Current Ratio is 3.89. IDEAYA Biosciences' value of 10.74 is 176.1% above this industry median. Based on the distribution chart, IDEAYA Biosciences ranks #284 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, IDEAYA Biosciences has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IDEAYA Biosciences' Current Ratio compare to MLYS and TARS?
According to the Biotechnology industry distribution chart, IDEAYA Biosciences ranks #284 out of 1417 companies for Current Ratio. This places IDEAYA Biosciences in the top 20% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. IDEAYA Biosciences' value of 10.74 is 176.1% above this benchmark. Historically, IDEAYA Biosciences' own Current Ratio has ranged from 4.50 to 28.42 over the past decade. While the company's 10-year median is 12.39 vs. the industry median of 3.89, IDEAYA Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEAYA Biosciences's current Current Ratio of 10.74 is 176.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEAYA Biosciences's current Current Ratio is 10.74, which is 13% below median its own 10-year median of 12.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEAYA Biosciences stock overvalued right now?
Based on GuruFocus' analysis, IDEAYA Biosciences (IDYA) is currently considered Possible Value Trap. The stock's GF Value™ is $214.33, compared to a current price of $36.30 — trading 83.1% below its estimated fair value. The current Current Ratio is 10.74, which is 13% below median its 10-year median of 12.39 and 176.1% above the Biotechnology industry median of 3.89. IDEAYA Biosciences' overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For IDEAYA Biosciences (IDYA), the current Current Ratio is 10.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEAYA Biosciences (IDYA) Overvalued in 2026?
Based on GuruFocus' analysis, IDEAYA Biosciences stock appears to be undervalued.
The current stock price of $36.30 is trading 83.1% below its estimated GF Value™ of $214.33.
GuruFocus considers IDEAYA Biosciences to be Possible Value Trap.
Key valuation signals for IDYA:
Current Ratio: 10.74 (13% below median its 10-year median of 12.39)
GF Value™: $214.33 vs. price of $36.30 (83.1% below fair value)
Industry Position: 176.1% above the Biotechnology median (#284 of 1417)
No single metric tells the full story. See the IDYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
55GF Score
Get the complete analysis for IDYA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDYA has been successfully added to your 
